申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP2518066A1
公开(公告)日:2012-10-31
The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I:
wherein,
X is N, or CR1d,
Xb1-Xb5 are the same or different, and are nitrogen or carbon,
R1a-R1d are the same or different, and are hydrogen, an optionally substituted aklyl, an optionally substituted alkoxy, an optionally substituted akylthio, an alkenyl, a cycloalkyl, a halogen, cyano, or hydroxyl or optionally substituted by 1 or 2 alkylamino,
R2 is an optionally substituted aryl or an optionally substituted heteroaryl,
R3 is an optionally substituted aryl or an optionally substituted heteroaryl, or
pharmaceutically acceptable salt thereof as an active ingredient.
本发明涉及一种新型抗血小板药剂和作为该药剂活性成分的新型化合物。本发明提供的抗血小板药剂由式 I 所代表的化合物组成:
其中
X是N,或CR1d、
Xb1-Xb5相同或不同,且为氮或碳、
R1a-R1d 相同或不同,并且是氢、任选取代的烷基、任选取代的烷氧基、任选取代的烷硫基、烯基、环烷基、卤素、氰基或羟基或任选被 1 或 2 个烷基氨基取代、
R2 是任选取代的芳基或任选取代的杂芳基、
R3 是任选取代的芳基或任选取代的杂芳基,或
作为活性成分的药学上可接受的盐。